119th Congress · introduced in the House · Mar 24, 2026
Candis King Hope for Sickle Cell Families Act
Official title from Congress.gov
Latest action (Mar 24, 2026): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
No cosponsors.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
1 citation.
SICKLE CELL DISEASE ASSOCIATION OF AMERICA · lobbying firm or registrant: ARTEMIS POLICY GROUP LLC
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Budget/Appropriations
$20,000
Paid to lobbying firm
Funding for federal sickle cell disease programs FY26 House and Senate Labor-HHS Appropriations bills FY27 House and Senate Labor-HHS Appropriations H.R. 8067, Candis King Hope for Sickle Cell Families Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing